Wendall Wierenga - Cytokinetics Independent Director


USD 41.00  1.71  4.35%   

Dr. Wendall Wierenga is Independent Director of the Company. Dr. Wierenga served as Executive Vice President, Research and Development, at Santarus, Inc., which was acquired by Salix Inc., which was subsequently acquired by Valeant Pharmaceuticals International, Inc. From 2006 to 2011, he served as Executive Vice President, Research and Development, at Ambit Biosciences Corporationrationration. From 2003 to 2006, he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. . From 1990 to 2000, he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at ParkeDavisWarner Lambert Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of XenoPort, Inc. from 2001 to August 2016, the Board of Directors of Ocera Therapeutics, Inc. since December 2013, the Board of Directors of Apricus Biosciences, Inc. and Concert Pharmaceuticals, Inc. since March 2014 and on the Board of Directors of Anacor Pharmaceuticals, Inc. from 2014 to July 2016. He also serves as the Chairman of the Board of Directors of a privately held pharmaceutical research and development company. Dr. Wierenga also served on the Board of Directors of Onyx Pharmaceuticals, Inc. from 1996 to 2013
Age: 70  Director Since 2011  Ph.D    
650 624-3000  www.cytokinetics.com
Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University.

Cytokinetics Management Efficiency

Cytokinetics has return on total asset (ROA) of (16.94) % which means that it has lost $16.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (120.54) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -63.24. The current Return on Average Assets is estimated to decrease to -0.33. The current Total Liabilities is estimated to increase to about 644.6 M. The current Current Liabilities is estimated to increase to about 77.5 M
The company currently holds 269.93 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. Cytokinetics has a current ratio of 7.3, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cytokinetics until it has trouble settling it off, either with new capital or with free cash flow. So, Cytokinetics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytokinetics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytokinetics to invest in growth at high rates of return. When we think about Cytokinetics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives


Amy Hood3M Company
Herbert Henkel3M Company
Linda Alvarado3M Company
Sondra Barbour3M Company
Pamela Craig3M Company
Patricia Woertz3M Company
Edward Liddy3M Company
Gregory Page3M Company
Robert Ulrich3M Company
Thomas Brown3M Company
Dambisa Moyo3M Company
Michael Eskew3M Company
Muhtar Kent3M Company
David Dillon3M Company
Vance Coffman3M Company
Ahmet Kent3M Company
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. Cytokinetics (CYTK) is traded on NASDAQ Exchange in USA. It is located in 350 Oyster Point Boulevard, South San Francisco, CA 94080, United States and employs 253 people. Cytokinetics is listed under Pharmaceutical Products category by Fama And French industry classification.

Cytokinetics Leadership Team

Elected by the shareholders, the Cytokinetics' board of directors comprises two types of representatives: Cytokinetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytokinetics. The board's role is to monitor Cytokinetics' management team and ensure that shareholders' interests are well served. Cytokinetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytokinetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Kaye, Director
Bradley Morgan, Senior Vice President - Drug Discovery and Early Development
Leonard Gage, Independent Chairman of the Board
Caryn McDowell, Chief Compliance Officer, Vice President General Counsel
Robert Wong, Chief Accounting Officer, Vice President
John Henderson, Independent Director
Sharon Barbari, CFO, Executive Vice President - Finance
Peter Roddy, Senior Vice President Chief Accounting Officer
Mark Schlossberg, Senior Vice President Legal and General Counsel
David Cragg, Sr. VP of HR
Elisabeth Schnieders, Senior Vice President - Business Development
Joanna Goldstein, IR Contact Officer
Wendall Wierenga, Independent Director
Santo Costa, Independent Director
Robert Califf, Director
Fady Malik, Senior Vice President - Research and Early Development
Wendell Wierenga, Independent Director
Lynne Parshall, Independent Director
Ching Jaw, CFO, Senior Vice President
Bonnie Charpentier, Sr. VP of Regulatory Affairs and Compliance
Robert Blum, CEO and President Director and Chief Executive of the Biopharmaceutical Concern
Sandford Smith, Independent Director
Andrew Wolff, Senior Vice President - Clinical Research and Development, Chief Medical Officer
Diane Weiser, IR Contact Officer

Cytokinetics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytokinetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now


Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
CEO Directory
Screen CEOs from public companies around the world
Transaction History
View history of all your transactions and understand their impact on performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Directory
Find actively traded corporate debentures issued by US companies
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.5 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.